Navigation Links
Breast cancer heterogeneity no barrier to predictive testing, study shows
Date:5/2/2013

Lugano-CH, Brussels-BE, 2 May 2013 -- Breast cancers contain many different cell types with different patterns of gene expression, but a new study provides reassurance that this variability should not be a barrier to using gene expression tests to help tailor cancer treatments to individual patients.

The findings were reported at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

In recent years it has become clear that breast cancers contain a variety of different cell types. An important result of this heterogeneity is that different biopsy specimens from a single breast cancer tumour can exhibit significant variability in genes expression.

This is a major concern for doctors seeking to understand which patients are likely to benefit from drugs designed to be effective against tumour cells with particular genetic characteristics. A number of studies at this year's IMPAKT conference consider this issue.

In one study, Dr Michał Jarząb and colleagues from the Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Poland took a total of 78 different biopsies from 26 individual tumours to assess the degree of genomic variation, and its impact on a set of 32 different prognostic and predictive multi-gene signatures.

"Some genomic tests have proven very useful in breast cancer, but in other important areas we have not achieved optimal results," Dr Jarząb explains. "One of these areas where we haven't done so well is in deciding whether a particular patient would benefit from certain type of chemotherapy or not, based on the material from pre-surgical needle biopsies. We hypothesized that some genomic tests may be prone to the heterogeneity of starting material and provide not reliable results."

The researchers performed gene expression profiling on their 78 samples using oligonucleotide microarrays. Overall, they found that the gene expression profiles of the cores were variable, and in at least 5 patients this heterogeneity was substantial.

However, when they analysed a number of multi-gene signatures selected from previous studies, this heterogeneity was considerably less significant.

The gene sets differed in their variance between biopsies, the authors found. The most pronounced heterogeneity was observed in immune response-related genes, while the least heterogeneous were the classifiers based on genes selected by advanced bioinformatical methods from both cell culture experiments and patient tissues.

"Overall, the heterogeneity among the potentially predictive genes was small enough and we conclude that this factor should not prohibit their effective use in clinical practice," Dr Jarząb says.

"Our study confirms that it is possible to address tumour heterogeneity when carrying out routine diagnostic procedures in patients. Our results may help to introduce the better tailoring of preoperative treatment."

Commenting on the results, Dr. Angelo Di Leo, Head of the Sandro Pitigliani Medical Oncology Unit and Chair of the Oncology Department at the Hospital of Prato, Istituto Toscano Tumori, Italy, said: "If other studies report similar results to this one, then it could become common practice to evaluate prognostic or predictive breast cancer markers from more than one primary tumour area."

"The study is innovative because it is one of the first to address the question of intratumour heterogeneity. It means that not all the cells from the same tumour have the same characteristics, and if we want to have a clear picture of the tumour biology we should not limit the evaluation of tumour markers to one area of the tumour itself," Dr. Di Leo said.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Big data analysis identifies prognostic RNA markers in a common form of breast cancer
2. Cold winters freezing out breast cancer treatment
3. Identified as responsible for breast and ovarian hereditary cancer 3 mutations at BRCA1 gene
4. An important discovery in breast cancer by IRCM researchers
5. UCLA researchers find nanodiamonds could improve effectiveness of breast cancer treatment
6. IMPAKT -- Translational research breast cancer conference
7. LSUHSC research discovers new drug target for metastatic breast cancer
8. AACR news: Studies show increasing evidence that androgen drives breast cancer
9. AACR news: Six2 homeoprotein allows breast cancer cells to detach and metastasize
10. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
11. Certain breast cancers have a trait that could be attacked by new therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... ... AMRI, a global contract research, development and manufacturing organization ... quality of life, will now be offering its impurity solutions as a stand-alone ... for all new drug products, including the finalization of ICH M7 earlier this ...
(Date:10/11/2017)... ... 11, 2017 , ... Personal eye wash is a basic first aid supply for any work ... which eye do you rinse first if a dangerous substance enters both eyes? It’s one ... with its unique dual eye piece. , “Whether its dirt and debris, or an ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... , ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled ... bold new look is part of a transformation to increase awareness, appeal to new ... , It will also expand its service offering from its signature gourmet cooking classes ...
Breaking Biology Technology: